Wael Zrafi
A5022956847- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Childhood Cancer Survivors' Quality of Life
- Radiomics and Machine Learning in Medical Imaging
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Head and Neck Cancer Studies
- Effects of Radiation Exposure
- Glioma Diagnosis and Treatment
- Tumors and Oncological Cases
- Radiation Therapy and Dosimetry
- Advanced Radiotherapy Techniques
- Ear and Head Tumors
- Medical Imaging Techniques and Applications
- Cancer, Hypoxia, and Metabolism
- Head and Neck Surgical Oncology
- Multiple and Secondary Primary Cancers
- Brain Metastases and Treatment
- Cancer Treatment and Pharmacology
- Renal and related cancers
- Nutrition and Health in Aging
- Testicular diseases and treatments
- Oral Health Pathology and Treatment
Institut Gustave Roussy
2020-2024
Université Paris-Saclay
2018-2024
Centre de recherche en Epidémiologie et Santé des Populations
2018-2024
Inserm
2018-2024
Université Paris-Sud
2020
Université d'Angers
2019
Hôpital Farhat Hached
2015-2018
Radiotherapie Groep
2018
Nearly 1% to 2% of NSCLCs harbor RET fusions. Characterization this rare population is still incomplete.This retrospective multicenter study included patients with any-stage positive (RET+) NSCLC from 31 cancer centers. Molecular profiling DNA/RNA sequencing or fluorescence in situ hybridization analyses. Clinicobiological features and treatment outcomes (per investigator) surgery, chemotherapy (CT), immune checkpoint blockers (ICBs), CT-ICB, multityrosine kinase inhibitors, inhibitors...
<p>supplementary materials</p>
<div>AbstractPurpose:<p>This study aimed to explore metabolic tumor volume (MTV) as assessed by 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG–PET/CT) and understand its biological meaning in patients with non–small cell lung cancer (NSCLC) exposed immune checkpoint blockers (ICB).</p>Experimental Design:<p>In this study, advanced NSCLC a positive PET scan within 42 days of first-line treatment were enrolled 11 institutions across...
Abstract Background: Childhood or adolescent cancer survivors are at increased risks of subsequent primary neoplasms (SPN) the central nervous system (CNS) after cranial irradiation. In a large multicentric cohort, we investigated clinical and therapeutic factors associated with long-term risk CNS SPN, quantified dose–response relationships. Methods: We selected all SPN cases diagnosed up to 2016 among members French Cancer Survivor Study least 5 years first diagnosis in 1946–2000. Four...
Between 10% and 20% of childhood cancer survivors (CCS) experience impaired growth, leading to small adult height (SAH). Our study aimed quantify risk factors for SAH or growth hormone deficiency among CCS.The French CCS Study holds data on 7,670 treated before 2001. We analyzed self-administered questionnaire from 2,965 with clinical, chemo/radiotherapy medical records. was defined as an ≤ 2 standard deviation scores control values obtained a population health study.After exclusion 189...
2632 Background: Genomic instability is a hallmark of cancer that has been associated to immune evasion, progression and multidrug resistance. In SAFIR02-Lung, advanced NSCLC pts were enrolled receive platinum-based chemotherapy. After 4 cycles, with no targetable alterations oriented the immunotherapy sub-study, if stable or in response, randomized between maintenance durvalumab Standard Care (SoC) (PMID 35802649). Durvalumab prolonged survival only PD-L1 ≥ 1% subgroup. this study we...
Background Survivors of childhood cancer are at risk subsequent primary neoplasms (SPNs), but the developing specific digestive SPNs beyond age 40 years remains uncertain. We investigated risks within largest available cohort worldwide. Methods The PanCareSurFup includes 69 460 five-year survivors from 12 countries in Europe. Risks were quantified using standardised incidence ratios (SIRs), absolute excess and cumulative incidence. Results 427 (214 colorectal, 62 liver, 48 stomach, 44...
Significance of tumor microenvironment (TME) features in EGFR-mutant (mut) Non-Small Cell Lung Cancer (NSCLC) is undefined. We explored their prognostic value advanced (a) EGFR-mut NSCLC. This a monocentric, retrospective study patients (pts) with aNSCLC EGFR exon 19 deletion (del19) /L858R positive (+) treated between 2008-2023. Whole Slide Images (20x magnified) from hematoxylin-eosin baseline slides were analyzed by pathologist and an oncologist, blinded to clinical data, describe TME....
Abstract Background: RET fusions are found in 1-2% of patients (pts) with advanced non-small cell lung cancer (aNSCLC). inhibitors (RETi) effective, but resistance occurs. Scarce data available on treatment after progression (PD) to RETi. Antibody-drug conjugates and bispecific antibodies promising therapies NSCLC, possibly employed at resistance. Data the expression membrane targets impact novel agents lacking. Methods: This is a multicentric retrospective study 6 European centers. We...
8535 Background: Despite remarkable advances with tyrosine kinase inhibitors (TKI), patients (pts) oncogene addicted advanced non-small cell lung cancer (aNSCLC) eventually face resistance. Moreover, some pts exhibit early TKI resistance, often linked to a reduced response subsequent TKIs. These might have unique biology, and identifying post-resistance treatments for them is an unmet need. Here, we explore the transcriptomic profile of aNSCLC progression, as compared long responders....
Abstract Purpose: This study aimed to explore metabolic tumor volume (tMTV) as assessed 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET/CT), and understand its biological meaning in patients with NSCLC exposed immune checkpoint blockers(ICBs). Experimental Design: In this study, advanced a positive PET scan within 42 days of first line treatment were enrolled 11 institutions across 4 countries. Total MTV was analyzed, 42% SUVmax threshold. Survival...
Immune checkpoint blockers (ICBs) revolutionized the treatment of patients with advanced non-small cell lung cancer (NSCLC) but only a fraction them obtain response, and clinical benefit from these treatments is often difficult to predict. The aim our study unveil potential implications antibody response previous viral infections in predicting ICBs NSCLC. Sera treated alone, chemotherapy (CT) or combination CT-ICBs were analyzed VirScan (CDI Labs, USA), high-throughput method that...
Radiation to the bone and exposure alkylating agents increases risk of cancer among survivors childhood cancer, but there is uncertainty regarding risks tissue radiation doses below 10 Gy dose-response relationship for specific types chemotherapy.Twelve European countries contributed 228 cases matched controls a nested case-control study within cohort 69,460 5-year cancer. Odds ratios (ORs) developing different levels cumulative chemotherapy were calculated. Excess ORs calculated investigate...
Abstract Background: RET fusions can be found in 1-2% of patients (pts) with advanced non-small cell lung cancer (aNSCLC). While targeted treatment inhibitors (RETi) has significantly improved prognosis, resistance eventually develops. Current knowledge regarding the pattern disease progression and optimal therapeutic sequence for treated RETi is limited. Methods: We conducted a retrospective multicentric collection clinical biological data on pts RET-rearranged (RET+) aNSCLC...
Abstract Background: Prognostic role of tumor microenvironment (TME) features, although well-studied in the context immunotherapy responses, remains unclear for oncogene-driven non-small cell lung cancer (NSCLC). Here, we interrogate impact TME features on survival outcomes patients with advanced EGFR-mutant NSCLC. Methods: A single-center, retrospective study was carried out (exon 19 deletion/L858R) NSCLC who underwent first-line targeted therapy or chemotherapy. Clinical, radiological,...